Conference item icon

Conference item

OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinumresistant ovarian cancer

Abstract:

Women with platinum resistant ovarian cancer (OC) have limited responses to standard therapy, and clinical trials with novel agents are therefore highly justified. Olaparib is a potent PARP inhibitor that has shown enhanced activity in women with relapsed BRCA-mutated OC in both platinum sensitive and resistant settings. Angiogenesis inhibitors, such as the oral tyrosine kinase inhibitor cediranib, are active in OC, and have shown additive effects when combined with PARP inhibitors preclinica...

Expand abstract
Publication status:
Published
Peer review status:
Reviewed (other)

Actions


Access Document


Publisher copy:
10.1093/annonc/mdx372.060

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Centre for Statistics in Medicine
Oxford college:
All Souls College
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Role:
Author
Publisher:
Oxford University Press
Host title:
NCRI Cancer Conference 2017
Journal:
2017 NCRI Cancer Conference More from this journal
Publication date:
2017-09-01
Acceptance date:
2017-07-21
DOI:
EISSN:
1569-8041
ISSN:
0923-7534
Pubs id:
pubs:738309
UUID:
uuid:a6dc966b-b572-43f2-9387-711f7b6aeaea
Local pid:
pubs:738309
Source identifiers:
738309
Deposit date:
2018-03-05

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP